Core Viewpoint - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies, which may signal potential investment opportunities or shifts in market sentiment. Group 1: Increased Holdings - Shandong Molong (00568) saw the largest increase in Hong Kong Stock Connect holdings, rising by 3.41% to a total holding of 58.38% [2] - ZTE Corporation (00763) experienced a 2.52% increase, bringing its holding to 54.86% [2] - Lens Technology (06613) increased by 2.22%, with a current holding of 11.01% [2] - Other notable increases include Southern Hang Seng Technology (03033) at +2.08% (60.66%) and Beijing Jingcheng Machinery Electric Company (00187) at +1.35% (49.54%) [2] Group 2: Decreased Holdings - Hang Seng China Enterprises (02828) had the largest decrease, down by 2.31% to 1.02% [2] - The Tracker Fund of Hong Kong (02800) decreased by 0.74%, now holding 1.87% [2] - Li Jin Technology (00558) saw a reduction of 0.69%, with a holding of 14.36% [2] - Other significant decreases include Ping An Good Doctor (01833) at -0.65% (19.25%) and Beijing North Star Company (00588) at -0.59% (41.42%) [2] Group 3: Five-Day Changes - Over the last five trading days, ZTE Corporation (00763) had the highest increase in holdings at +7.26% (54.86%) [3] - Longpan Technology (02465) increased by 6.03% to 51.76% [3] - Tongyuan Kang Pharmaceutical-B (02410) rose by 5.38%, now at 14.68% [3] - Significant decreases included Dongyang Sunshine Pharmaceutical (06887) at -3.85% (44.05%) and Zhejiang Shibao (01057) at -2.73% (55.74%) [3] Group 4: Twenty-Day Changes - Longfei Optical Fiber and Cable (06869) had the largest increase over twenty days at +22.04% (56.07%) [4] - Meizhong Jiahe (02453) increased by 12.55% to 37.75% [4] - Other notable increases include Yimai Sunshine (02522) at +11.66% (40.40%) and Kanglong Chemical (03759) at +9.51% (59.33%) [4] - Decreases over twenty days included Chongqing Steel (01053) at -5.91% (32.47%) and Dongfang Electric (01072) at -5.60% (37.80%) [4]

Core Viewpoint - The article highlights the successful transformation of traditional pharmaceutical companies towards innovative drug development, driven by the implementation of drug procurement policies since 2018, which pressured companies reliant on generic drug revenues to adapt and innovate [3][7]. Group 1: Performance of Pharmaceutical Companies - Heng Rui Medicine reported a revenue of 15.762 billion yuan in the first half of 2025, a year-on-year increase of 15.88%, with a net profit of 4.45 billion yuan, up 29.67% [5]. - In the same period, Heng Rui's innovative drug sales and licensing income reached 9.561 billion yuan, accounting for 60.66% of total revenue, with innovative drug sales alone at 7.570 billion yuan [6]. - Hansoh Pharmaceutical achieved approximately 6.145 billion yuan in innovative drug and cooperative product sales, a 22.1% increase, making up 82.7% of total revenue [7]. - Yuan Da Pharmaceutical reported a record revenue of approximately 6.11 billion HKD, with innovative and barrier products accounting for about 51% of total revenue, a nearly 15 percentage point increase year-on-year [7]. - Xiansheng Pharmaceutical's total revenue grew by 15.1% to 3.585 billion yuan, with innovative drug revenue reaching 2.776 billion yuan, a 26% increase, and accounting for 77.4% of total revenue [8]. Group 2: R&D Investments and Internationalization - Heng Rui Medicine invested 3.871 billion yuan in R&D in the first half of 2025, with cumulative R&D investments exceeding 48 billion yuan [9]. - Xiansheng Pharmaceutical reported an R&D investment rate of 28.7%, with over 10 billion yuan invested in the past decade [10]. - China National Pharmaceutical's innovative drug revenue accounted for 44.4% of total revenue, with plans to enhance its innovative drug business through acquisitions, including a recent 500 million USD acquisition of a Shanghai-based innovative drug company [10]. - The article notes that while many pharmaceutical companies are increasing R&D investments, their innovative drug sales are primarily focused on the domestic market, with limited international presence [11]. - Heng Rui has established 15 external authorization collaborations, emphasizing a strategy of combining independent R&D with international partnerships to enhance global market penetration [12]. - Xiansheng Pharmaceutical is accelerating its global layout with successful dual clinical trials in China and the U.S., aiming for sustainable growth through international collaborations [13].

Core Insights - The pharmaceutical industry is witnessing a significant transformation towards innovation, with many companies reporting that innovative drugs now account for over half of their revenues [1] Group 1: Company Performance - Heng Rui Medicine reported a revenue of 15.762 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, with net profit reaching 4.45 billion yuan, up 29.67% [2] - Heng Rui's innovative drug sales and licensing income amounted to 9.561 billion yuan, representing 60.66% of total revenue, with innovative drug sales reaching 7.570 billion yuan [2] - Han Sen Pharmaceutical achieved approximately 6.145 billion yuan in innovative drug and cooperative product sales, a year-on-year increase of 22.1%, accounting for about 82.7% of total revenue [3] - Han Sen's total revenue for the first half of 2025 was 7.434 billion yuan, up 14.3%, with net profit of 3.135 billion yuan, a 15% increase [4] - Yuan Da Pharmaceutical reported a record revenue of approximately 6.11 billion HKD, with innovative and barrier products accounting for about 51% of total revenue, a nearly 15 percentage point increase year-on-year [4] - Xian Sheng Pharmaceutical's total revenue grew by 15.1% to 3.585 billion yuan, with adjusted net profit of 651 million yuan, up 21.1%, driven by innovative drug revenue [4] Group 2: R&D Investment - Heng Rui Medicine invested 3.871 billion yuan in R&D in the first half of 2025, with cumulative R&D investment exceeding 48 billion yuan [5] - Xian Sheng Pharmaceutical reported an R&D investment rate of 28.7%, with cumulative R&D investment exceeding 10 billion yuan over the past decade [5] Group 3: Market Expansion and Challenges - China National Pharmaceutical's innovative drug revenue accounted for 44.4% of total revenue, with plans to enhance its innovative drug business through acquisitions, including a recent acquisition of a Shanghai-based innovative drug company for 500 million USD [6] - Despite the growth in innovative drug sales, most companies are still primarily focused on the domestic market, with limited international presence [6][7] - Heng Rui has established 15 external licensing collaborations and is actively seeking partnerships with global pharmaceutical companies to enhance international market penetration [8] - Xian Sheng Pharmaceutical is accelerating its global layout, having achieved three self-researched products going overseas, with external licensing expected to be a sustainable growth source [8]

Group 1 - The company, Heng Rui Medicine (01276.HK), has received approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-6093 tablets [1] - The clinical trials for HRS-6093 will commence shortly following the approval [1]

Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-2162 injection, a new generation muscle relaxant antagonist [1] Group 1 - HRS-2162 injection is designed to counteract the pharmacological effects of muscle relaxants and rapidly restore muscle tone [1] - Currently, there are no similar products approved for marketing in both domestic and international markets [1] - The total research and development investment for the HRS-2162 injection project has reached approximately 28.25 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for the clinical trial of HRS-6093 tablets, a novel and selective oral KRAS G12D inhibitor aimed at targeting KRAS G12D mutation proteins for anti-tumor effects [1] Group 1 - The company has announced the approval of a clinical trial for HRS-6093 tablets [1] - HRS-6093 is characterized as a new, efficient, and selective oral KRAS G12D inhibitor [1] - The drug specifically binds to KRAS G12D mutated proteins to exert anti-tumor effects [1]

格隆汇8月25日丨恒瑞医药(01276.HK)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药 监局核准签发关于HRS-2162注射液的《药物临床试验批准通知书》，将于近期开展临床试验。HRS- 2162注射液是新一代肌松药拮抗剂，可拮抗肌松药的药理作用，快速恢复肌张力。目前国内外尚无同类 产品获批上市。 ...

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of HRS-6093, a novel oral KRAS G12D inhibitor, which is expected to have significant anti-tumor effects [1] Group 1 - The clinical trial approval for HRS-6093 indicates a strategic advancement in the company's oncology pipeline [1] - HRS-6093 is a selective and efficient oral inhibitor specifically targeting the KRAS G12D mutation, which is crucial for certain cancer treatments [1] - Currently, there are no similar products approved for market in both domestic and international markets, highlighting a potential competitive advantage for the company [1] Group 2 - The total research and development investment for the HRS-6093 project has reached approximately 29.84 million yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月25日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-12 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月25日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码 ...